Cargando…

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting Sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Bin, Li, Dan, Xu, Ting, Luo, Min, He, Zhiyao, Li, Yuwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878877/ https://www.ncbi.nlm.nih.gov/pubmed/33574396 http://dx.doi.org/10.1038/s41598-021-83099-y

Ejemplares similares

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
por: Wu, Bin, et al.
Publicado: (2021)

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
por: Wang, Liwei, et al.
Publicado: (2017)

Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database
por: Zeng, Yifan, et al.
Publicado: (2021)

Proton Pump Inhibitors and the Risk of Adverse Cardiac Events
por: Juurlink, David N., et al.
Publicado: (2013)

Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis
por: Boonpheng, Boonphiphop, et al.
Publicado: (2019)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

1783. Acute Kidney Injury Associations with Antibiotics: A Pharmacovigilance Study of the US FDA Adverse Event Reporting System
por: Kochuparambil, Jose J, et al.
Publicado: (2023)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
por: Bai, Yang, et al.
Publicado: (2023)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients
por: Douwes, Rianne M., et al.
Publicado: (2019)

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
por: Altebainawi, Ali F., et al.
Publicado: (2023)

Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?
por: Tan, Hui Zhuan, et al.
Publicado: (2023)

Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist?
por: Toth-Manikowski, Stephanie M., et al.
Publicado: (2017)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2023)

Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children
por: Li, Yanqin, et al.
Publicado: (2020)

Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
por: Hu, Yang, et al.
Publicado: (2020)

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication
por: Guérin, Annie, et al.
Publicado: (2016)

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
por: Wu, Bin, et al.
Publicado: (2022)

Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility
por: Fossmark, Reidar, et al.
Publicado: (2019)

Adverse Effects Associated with Proton Pump Inhibitor Use
por: Yibirin, Marcel, et al.
Publicado: (2021)

Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
por: Kong, Qingli, et al.
Publicado: (2023)

Proton pump inhibitors are associated with increased risk of development of chronic kidney disease
por: Arora, Pradeep, et al.
Publicado: (2016)

Pharmacoepidemiology for nephrologists: do proton pump inhibitors cause chronic kidney disease?
por: Tomlinson, Laurie A., et al.
Publicado: (2017)

Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease
por: Hughes, John, et al.
Publicado: (2018)

The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients
por: Flothow, Dominik J. G., et al.
Publicado: (2020)

Impact of proton pump inhibitors on the onset of gastrointestinal immune‐related adverse events during immunotherapy
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis
por: Li, Mei-Juan, et al.
Publicado: (2017)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Proton pump inhibitors and acute kidney injury: a nested case–control study
por: Klepser, Donald G, et al.
Publicado: (2013)

Proton-Pump Inhibitors and Serum Concentrations of Uremic Toxins in Patients with Chronic Kidney Disease
por: El Chamieh, Carolla, et al.
Publicado: (2023)

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies
por: Wu, Chieh-Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uctq650lhu93k91a23qibqp1lk